Table 1. Visual acuity change from baseline at one year among genotype groups of VEGFR2 SNPs rs4576072 and rs6828477 in CATT and IVAN.

	Ranibizumab and Bevacizumab Combined			Ranibizumab only
SNP Genotype	n (%)	Change in visual acuity (letters) Mean (SD)	P for comparison with TT§	n (%)	Change in visual acuity (letters) Mean (SD)	P for comparison with TT§
		CATT (N=835)			CATT (N=432)
rs4576072		Linear Trend P=0.77			Linear trend P=0.66
TT	595 (71)	8.2 (14.5)		312 (72)	8.7 (12.8)
CT	219 (26)	8.3 (13.6)	0.90	111 (26)	9.9 (12.5)	0.41
CC	21 (3)	5.9 (11.3)	0.46	9 (2)	6.7 (13.0)	0.63
CT or CC	240 (29)	8.1 (13.4)	0.94	120 (28)	9.6 (12.6)	0.50
rs6828477		Linear Trend P=0.20			Linear trend P=0.01
TT	250 (30)	9.2 (13.7)		132 (31)	10.6 (11.2)
CT	454 (54)	7.8 (14.2)	0.20	230 (53)	9.1 (12.6)	0.29
CC	131 (16)	7.5 (14.8)	0.26	70 (16)	5.5 (15.0)	0.007
CT or CC	585 (70)	7.7 (14.4)	0.16	300 (69)	8.3 (13.3)	0.09
		IVAN (N=512)*			IVAN (N=271)
rs4576072		Linear trend P=0.53			Linear trend P= 0.56
TT	364 (71)	6.0 (11.9)		196 (72)	6.4 (11.9)
CT	124 (24)	4.2 (11.4)	0.19	60 (22)	5.6 (12.3)	0.67
CC	20 (4)	7.4 (18.8)	0.62	12 (4)	11.5 (17.4)	0.19
CT or CC	144 (28)	4.7 (12.5)	0.30	72 (27)	6.5 (13.0)	0.93
rs6828477		Linear trend P=0.97			Linear trend P= 0.13
TT	185 (36)	5.0 (12.0)		95 (35)	5.1 (12.8)
CT	221 (43)	6.6 (11.8)	0.22	121 (45)	6.6 (11.2)	0.39
CC	105 (21)	4.7 (12.8)	0.81	55 (20)	8.3 (13.2)	0.14
CT or CC	326 (64)	5.9 (12.1)	0.43	176 (65)	7.2 (11.8)	0.21

SD = standard deviation, SNP=single nucleotide polymorphism, VA=visual acuity.

CATT = Comparison of AMD Treatments Trials.

IVAN = Alternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularization.

^§P values were calculated using analysis of variance.

^*Invalid genotype data occurred in 4 patients for rs4576072 and 1 patient for rs6828477 and were excluded from the statistical analysis.